Our global Life Sciences team comprises a multi-disciplinary group of professionals, acting for businesses across the pharmaceuticals, biotech, veterinary, consumer health, med tech, and diagnostics sub-sectors.
Our experts advise across the entire product cycle - from product development, clinical trials to market entry, advice on reimbursement claims in Germany and pan-European locations, and post-market pharmacovigilance.
The sector team operates on a cross-border basis and covers the full spectrum of legal support. We advise on mergers and acquisitions, IP (both contentious and non-contentious), regulatory, dispute resolution, commercial transactions (including licensing and collaborations) as well as capital markets and finance.
Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are in the pole position to advise on cross-border work.
News and insights
News: 30 November 2023
Allen & Overy today announced that renowned life sciences specialist Dr Anna Wolters-Höhne has joined the firm’s intellectual property litigation practice with effect from 1 December 2023. Anna joins…
Blog Post: 17 July 2023
G1/23 – EPO Enlarged Board of Appeals of the EPO “available” (referral from T 0438/19) Under which circumstances can the public prior use of a product constitute prior art for novelty or inventive…
Blog Post: 28 November 2022
Keeping up with current developments regarding pricing and reimbursement of pharmaceuticals is crucial for planning efficient and successful market access strategies. The regulatory framework…
Publications: 28 July 2022
The equity capital markets have faced challenging conditions in H1 2022. European markets cooled, the Middle East boomed.